89 related articles for article (PubMed ID: 15364641)
1. Inhibition of COX isoforms by nutraceuticals.
Seaver B; Smith JR
J Herb Pharmacother; 2004; 4(2):11-8. PubMed ID: 15364641
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cyclooxygenase (COX) enzymes by compounds from Daucus carota L. Seeds.
Momin RA; De Witt DL; Nair MG
Phytother Res; 2003 Sep; 17(8):976-9. PubMed ID: 13680840
[TBL] [Abstract][Full Text] [Related]
4. Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures.
Waffo-Téguo P; Hawthorne ME; Cuendet M; Mérillon JM; Kinghorn AD; Pezzuto JM; Mehta RG
Nutr Cancer; 2001; 40(2):173-9. PubMed ID: 11962253
[TBL] [Abstract][Full Text] [Related]
5. Involvement of cyclooxygenase-derived prostaglandin E2 and nitric oxide in the protection of rat pancreas afforded by low dose of lipopolysaccharide.
Jaworek J; Bonior J; Tomaszewska R; Jachimczak B; Kot M; Bielański W; Pawlik WW; Sendur R; Stachura J; Konturek PC; Konturek SJ
J Physiol Pharmacol; 2001 Mar; 52(1):107-26. PubMed ID: 11321505
[TBL] [Abstract][Full Text] [Related]
6. Kinetic basis for selective inhibition of cyclo-oxygenases.
Gierse JK; Koboldt CM; Walker MC; Seibert K; Isakson PC
Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):607-14. PubMed ID: 10215599
[TBL] [Abstract][Full Text] [Related]
7. Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracaena loureiri.
Likhitwitayawuid K; Sawasdee K; Kirtikara K
Planta Med; 2002 Sep; 68(9):841-3. PubMed ID: 12357401
[TBL] [Abstract][Full Text] [Related]
8. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model.
Ehrich EW; Dallob A; De Lepeleire I; Van Hecken A; Riendeau D; Yuan W; Porras A; Wittreich J; Seibold JR; De Schepper P; Mehlisch DR; Gertz BJ
Clin Pharmacol Ther; 1999 Mar; 65(3):336-47. PubMed ID: 10096266
[TBL] [Abstract][Full Text] [Related]
9. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 inhibitors: promise or peril?
Mengle-Gaw LJ; Schwartz BD
Mediators Inflamm; 2002 Oct; 11(5):275-86. PubMed ID: 12467519
[TBL] [Abstract][Full Text] [Related]
11. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells.
Fiebich BL; Grozdeva M; Hess S; Hüll M; Danesch U; Bodensieck A; Bauer R
Planta Med; 2005 Jan; 71(1):12-9. PubMed ID: 15678367
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
[TBL] [Abstract][Full Text] [Related]
13. COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro.
Mohseni H; Zaslau S; McFadden D; Riggs DR; Jackson BJ; Kandzari S
J Surg Res; 2004 Jun; 119(2):138-42. PubMed ID: 15145695
[TBL] [Abstract][Full Text] [Related]
14. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
[TBL] [Abstract][Full Text] [Related]
15. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events.
Tanaka A; Hase S; Miyazawa T; Ohno R; Takeuchi K
J Pharmacol Exp Ther; 2002 Dec; 303(3):1248-54. PubMed ID: 12438549
[TBL] [Abstract][Full Text] [Related]
16. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes.
Blanco FJ; Guitian R; Moreno J; de Toro FJ; Galdo F
J Rheumatol; 1999 Jun; 26(6):1366-73. PubMed ID: 10381057
[TBL] [Abstract][Full Text] [Related]
17. COX-1 and COX-2 inhibitors.
Hawkey CJ
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
[TBL] [Abstract][Full Text] [Related]
18. [Clinical application of cyclooxygenase-2 inhibitors].
Dzielska-Olczak M; Olczak S
Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
[TBL] [Abstract][Full Text] [Related]
19. 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors.
Ranatunge RR; Earl RA; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Schwalb DJ; Young DV; Zemtseva IS
Bioorg Med Chem Lett; 2004 Dec; 14(24):6049-52. PubMed ID: 15546727
[TBL] [Abstract][Full Text] [Related]
20. Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.
Noreen Y; Ringbom T; Perera P; Danielson H; Bohlin L
J Nat Prod; 1998 Jan; 61(1):2-7. PubMed ID: 9461646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]